Kenvue Inc. (NYSE:KVUE) Shares Sold by Nuance Investments LLC

Nuance Investments LLC lowered its holdings in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 67.2% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 379,568 shares of the company's stock after selling 778,996 shares during the quarter. Nuance Investments LLC's holdings in Kenvue were worth $8,779,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in KVUE. Kingsview Wealth Management LLC purchased a new stake in shares of Kenvue in the 1st quarter worth $253,000. Covestor Ltd purchased a new stake in shares of Kenvue during the 1st quarter worth $109,000. O Shaughnessy Asset Management LLC lifted its stake in shares of Kenvue by 34.3% during the 1st quarter. O Shaughnessy Asset Management LLC now owns 30,765 shares of the company's stock worth $660,000 after purchasing an additional 7,854 shares during the last quarter. Axxcess Wealth Management LLC purchased a new stake in shares of Kenvue during the 1st quarter worth $255,000. Finally, Advisors Asset Management Inc. purchased a new stake in shares of Kenvue during the 1st quarter worth $206,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Kenvue Trading Up 0.4 %

KVUE stock traded up $0.09 during midday trading on Wednesday, hitting $23.78. 7,413,867 shares of the company's stock were exchanged, compared to its average volume of 17,954,916. The business has a 50-day simple moving average of $22.79 and a two-hundred day simple moving average of $20.78. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The stock has a market capitalization of $45.59 billion, a PE ratio of 43.07, a P/E/G ratio of 2.16 and a beta of 1.36. Kenvue Inc. has a 1-year low of $17.67 and a 1-year high of $24.13.

Kenvue (NYSE:KVUE - Get Free Report) last issued its quarterly earnings data on Thursday, November 7th. The company reported $0.28 earnings per share for the quarter, beating analysts' consensus estimates of $0.27 by $0.01. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. The business had revenue of $3.90 billion during the quarter, compared to analysts' expectations of $3.92 billion. During the same period in the previous year, the firm posted $0.31 earnings per share. The company's revenue was down .4% on a year-over-year basis. On average, sell-side analysts predict that Kenvue Inc. will post 1.07 EPS for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, November 27th. Shareholders of record on Wednesday, November 13th will be issued a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a yield of 3.45%. The ex-dividend date is Wednesday, November 13th. Kenvue's dividend payout ratio (DPR) is 149.09%.

Analysts Set New Price Targets

KVUE has been the topic of several recent analyst reports. JPMorgan Chase & Co. upped their target price on Kenvue from $24.00 to $25.00 and gave the company an "overweight" rating in a research report on Friday, October 11th. Bank of America increased their price objective on Kenvue from $24.00 to $27.00 and gave the company a "buy" rating in a report on Tuesday, October 22nd. UBS Group increased their price objective on Kenvue from $20.00 to $22.00 and gave the company a "neutral" rating in a report on Wednesday, August 7th. Royal Bank of Canada lowered Kenvue from an "outperform" rating to a "sector perform" rating and set a $24.00 price objective on the stock. in a report on Tuesday, September 24th. Finally, Deutsche Bank Aktiengesellschaft raised their target price on Kenvue from $23.00 to $24.00 and gave the stock a "buy" rating in a report on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $22.64.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.